Lin BioScience, Inc.

銵?鋆蔭?詨

FIRST-IN-CLASS

DRUG TREATMENTS

Lin BioScience is focused on discovering and developing innovative
drug candidate for the treatment of cancer and eye diseases

ORAL DRUG TREATMENT

for MACULAR DEGENERATION

First-in-Class oral therapeutic candidate for Dry Age-related Macular Degeneration and Stargardt Disease

TARGET THERAPY

with BROAD ONCOLOGY APPLICATIONS

Natural small molecular inhibitor for treatment of broad variety of cancers

NEWS

Jul 09 , 2021 Belite Bio Announces Start of LBS-008 Phase 3 Stargardt Disease Trial Lin BioScience’s subsidiary, Belite Bio, a clinical stage biopharmaceutical drug development company announced the initiation of Phase 3 clinical trial in Stargardt disease for tinlarebant (LBS-008).

Sep 16 , 2020 Lin BioScience raises $30 million in its rights issue to support LBS-008’s phase 3 clinical trial to treat Stargardt disease Lin BioScience today announced that it has successfully completed its $30 million Rights Issue. The new funding will enable Lin BioScience to continue to invest in its subsidiary Belite Bio to pursue the Phase 3 clinical trial of its lead RBP4 antagonist LBS-008 for Stargardt disease.

Apr 24 , 2019 Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease U.S. Food and Drug Administration has approved its Investigational New Drug application for LBS-008 (BPN-14967), a first-in-class oral therapy for the treatment of atrophic Age-related Macular Degeneration and Stargardt disease.

THERAPEUTIC AREAS